The management of psychosis in movement disorder patients (Q36808034)

16 August 2017

1 reference

title

The management of psychosis in movement disorder patients (English)

1 reference

16 August 2017

1 reference

3

Joseph H Friedman

1 reference

16 August 2017

Kelvin L Chou

1

1 reference

PubMed ID

17472539

16 August 2017

Leora L Borek

series ordinal

2

1 reference

PubMed ID

17472539

16 August 2017

language of work or name

English

0 references

publication date

1 May 2007

1 reference

Expert Opinion on Pharmacotherapy

16 August 2017

1 reference

16 August 2017

8

1 reference

16 August 2017

7

1 reference

16 August 2017

935-943

1 reference

Combating psychosis in Parkinson's disease patients: the use of antipsychotic drugs

16 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Caregiver-burden in parkinson's disease is closely associated with psychiatric symptoms, falls, and disability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Risk factors for nursing home placement in advanced Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Visual hallucinations associated with Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Prospective study of hallucinations and delusions in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Visual hallucinations in Parkinson's disease: a review and phenomenological survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Clozapine-responsive tremor in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Clozapine: a 2-year open trial in Parkinson's disease patients with psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Risperidone for hallucinations in levodopa-treated Parkinson's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Olanzapine treatment for dopaminergic-induced hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Use of ziprasidone in parkinsonian patients with psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Ziprasidone and psychosis in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Donepezil in the treatment of hallucinations and delusions in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Risperidone in the treatment of psychoses in the elderly: a case report series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Rivastigmine for dementia associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Dementia associated with Lewy bodies: dilemmas and directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Characteristics of visual hallucinations in Parkinson disease dementia and dementia with lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Improvement of both psychotic symptoms and Parkinsonism in a case of dementia with Lewy bodies by the combination therapy of risperidone and L-DOPA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Neuroleptic sensitivity to risperidone in Lewy body dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with Lewy bodies: A case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Psychopathology in Huntington's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Neuropsychiatric aspects of Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Risperidone in chorea and psychosis of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

Treatment of Huntington's disease with galantamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.935

21 January 2018

Identifiers

DOI

10.1517/14656566.8.7.935

1 reference

16 August 2017

1 reference

PubMed ID

17472539